

Shaun R Stauffer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9586297/publications.pdf>

Version: 2024-02-01

24
papers

950
citations

759233

12
h-index

610901

24
g-index

25
all docs

25
docs citations

25
times ranked

1764
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery, Synthesis, And Structure-Based Optimization of a Series of <i>N</i> -(<i>tert</i> -Butyl)-2-(<i>N</i> -arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 534-546.	6.4	178
2	Advancing Biological Understanding and Therapeutics Discovery with Small-Molecule Probes. <i>Cell</i> , 2015, 161, 1252-1265.	28.9	135
3	respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: Identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 6172-6177.	2.2	113
4	Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CL ^{pro}). <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2880-2904.	6.4	78
5	Targeting zoonotic viruses: Structure-based inhibition of the 3C-like protease from bat coronavirus HKU4. The likely reservoir host to the human coronavirus that causes Middle East Respiratory Syndrome (MERS). <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 6036-6048.	3.0	65
6	Progress toward Positive Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5 (mGlu ₅). <i>ACS Chemical Neuroscience</i> , 2011, 2, 450-470.	3.5	56
7	mGlu ₅ positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome. <i>Human Molecular Genetics</i> , 2016, 25, 1990-2004.	2.9	48
8	Chemical inhibition of fatty acid absorption and cellular uptake limits lipotoxic cell death. <i>Biochemical Pharmacology</i> , 2015, 98, 167-181.	4.4	43
9	Discovery of VU0409551/JNJ-46778212: An mGlu ₅ Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 716-720.	2.8	41
10	Relationship between In Vivo Receptor Occupancy and Efficacy of Metabotropic Glutamate Receptor Subtype 5 Allosteric Modulators with Different In Vitro Binding Profiles. <i>Neuropsychopharmacology</i> , 2015, 40, 755-765.	5.4	40
11	Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists: Discovery and SAR of ML354. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 4708-4713.	2.2	35
12	Contributions of Protease-Activated Receptors PAR1 and PAR4 to Thrombin-Induced GPIIb/IIIa Activation in Human Platelets. <i>Molecular Pharmacology</i> , 2017, 91, 39-47.	2.3	29
13	Platelet olfactory receptor activation limits platelet reactivity and growth of aortic aneurysms. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	18
14	Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetration. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 3822-3825.	2.2	11
15	The discovery of VU0486846: steep SAR from a series of M1 PAMs based on a novel benzomorpholine core. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 2175-2179.	2.2	10
16	Discovery and SAR of novel series of imidazopyrimidinones and dihydroimidazopyrimidinones as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu ₅). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 1310-1317.	2.2	9
17	Discovery and SAR of muscarinic receptor subtype 1 (M1) allosteric activators from a molecular libraries high throughput screen. Part 1: 2,5-Dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones as positive allosteric modulators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 384-388.	2.2	9
18	Discovery and SAR of a novel series of metabotropic glutamate receptor 5 positive allosteric modulators with high ligand efficiency. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 3641-3646.	2.2	7

#	ARTICLE	IF	CITATIONS
19	Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 3515-3519.	2.2	7
20	Preliminary investigation of 6,7-dihydropyrazolo[1,5- a]pyrazin-4-one derivatives as a novel series of mGlu 5 receptor positive allosteric modulators with efficacy in preclinical models of schizophrenia. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 429-434.	2.2	7
21	Acyl dihydropyrazolo[1,5-a]pyrimidinones as metabotropic glutamate receptor 5 positive allosteric modulators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 5115-5120.	2.2	5
22	Discovery of Small-Molecule Nonfluorescent Inhibitors of Fluorogen-Fluorogen Activating Protein Binding Pair. <i>Journal of Biomolecular Screening</i> , 2016, 21, 74-87.	2.6	2
23	Aminopyridine analogs selectively target metastatic pancreatic cancer. <i>Oncogene</i> , 2022, 41, 1518-1525.	5.9	2
24	Peripheral sTREM2-Related Inflammatory Activity Alterations in Early-Stage Alzheimer's Disease. <i>Journal of Immunology</i> , 2022, 208, 2283-2299.	0.8	2